Cargando…
Infections in Patients with Rheumatoid Arthritis in the Era of Targeted Synthetic Therapies
The third decade of the 21(st) century marks the beginning of a new era in the treatment of rheumatoid arthritis (RA). Recently, after the introduction in clinical practice of different biologics in the first decade, three different oral synthetic targeted agents (JAK inhibitors) have been licensed...
Autores principales: | Thomas, Konstantinos, Vassilopoulos, Dimitrios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Mediterranean Journal of Rheumatology (MJR)
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361184/ https://www.ncbi.nlm.nih.gov/pubmed/32676571 http://dx.doi.org/10.31138/mjr.31.1.129 |
Ejemplares similares
-
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
por: Grigoropoulos, Ioannis, et al.
Publicado: (2019) -
Study of the natural course and specific immunity after herpes zoster in patients with rheumatoid arthritis receiving biologic DMARDs
por: Thomas, Konstantinos, et al.
Publicado: (2017) -
Twenty Years of Targeted Treatment in Rheumatoid Arthritis in the Greek Databases: Achievements and Unmet Needs
por: Sidiropoulos, Prodromos, et al.
Publicado: (2019) -
Nutrition and Rheumatoid Arthritis in the ‘Omics’ Era
por: Cassotta, Manuela, et al.
Publicado: (2021) -
Targeted therapies in rheumatoid arthritis: Focus on rituximab
por: Teng, YKO, et al.
Publicado: (2007)